Blood cancer

January 25, 2021
PrECOG logo

Trial Spotlight: Jonathan Cohen, MD on Trial PrE0404 for Relapsed/Refractory Mantle Cell Lymphoma

This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma